Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1191)	1/4/2000 9:36:00 AM
From: aknahow	Read Replies (1) \| Respond to of 1686

For those interested the data on the P II Anti-CD11a or hu1124 of Genentech is available from XOMA. The P II involved fewer subjects, (90) than the Amevive P II. It had 30 in the .3 mg/kg treatment arm. So the dose was twice that of the highest Amevive dose. Treatment however was for 8 wks. vs 12. Population was subjects with moderate to severe psoriasis over 10% or more of their body surface with a PASI score of at least 12. Evaluation was done at 56 days 8 weeks. Follow up at 91 days after last treatment and followed until CD11a expression on CD+ T lymphocytes is at least 80% of baseline for at least 140 days. Acute adverse effects, within 24 hours of dosing, were provide in the data for all three arms of the trial. I could not find this information for the Amevive trial. I am not able to draw a meaningful conclusion from this information. Any help would be appreciated.